SpikImm
Company Details
Status: Private
Employees: 1-10
Location:
Paris, France
Type:
sample
Technology:
sample
sample
sample
About: SpikImm was founded in 2021 by Truffle Capital and the Institut Pasteur to develop human monoclonal antibodies (mAbs) to prevent COVID-19 infection.
SPK001, SpikImm’s lead candidate, originally developed in the laboratory of Humoral Immunology (Institut Pasteur) headed by Dr Hugo MOUQUET, has demonstrated a potent and broad neutralization activity in vitro against SARS-CoV-2 and all pathogenic variants (including Delta and Omicron), as well as a therapeutic efficacy in vivo in mouse and hamster models.
SPK001 is developed as a long-acting antibody with a convenient, intramuscular administration for the prevention of COVID-19 (pre-exposure prophylaxis) in immunocompromised patients unable to mount a protective antibody response after vaccination.
SpikImm expects to start clinical trials mid-2022.
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
SpikImm | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.